and the TEAM-2* Study Investigators Thrombolytic therapy has been shown to improve clinical outcome when administered early after the onset of symptoms of acute myocardial infarction; the mechanism of benefit is believed to be reestablishment and maintenance of coronary artery patency. Anistreplase is a second generation thrombolytic agent that is easily administered and has a long duration of ...

in cerebrovascular disease is presently available. Of the two statistically controlled therapeutic trials that have been published, the first with a plasmin/ streptokinase mixture (Thrombolysin) suggested that the treatment was without value, while the second trial of streptokinase plus anticoagulants versus a control group of anticoagulant-treated patients suggested that though lysis of the ca...

Thrombolytic therapy has been a major milestone in the management of acute myocardial infarction. By restoring patency in the infarct-related vessel, early administration of thrombolytic therapy reduces the extent of myocardial damage, lowers the risk of morbidity, and prolongs survival. Importantly, however, the available thrombolytic agents have several limitations that may result in less tha...

Antioxidants lavishly present in many natural source attributed their capability of slowing or preventing the oxidation of other molecules, helpful in the prevention of many age-related diseases and promotion of health. This study is designed to evaluate the antioxidant properties of the methanolic leaf extracts of Abroma augusta. After collection, drying, grinding and extraction, final extract...

A prospective interventional study was carried out to compare the thrombolytic effect of streptokinase between diabetic and non-diabetic myocardial infarction patients. Out of 187 study subjects with acute ST segment elevation myocardial infarction, admitted at coronary care unit, 126 patients were nondiabetic and 61 patients were diabetic. Streptokinase was administered to all patients. Resolu...

The measurement of anti-streptokinase antibodies can distinguish the patients who may benefit from streptokinase and those who should be treated with some other thrombolytic regimen. Neutralising titration test is a commonly used classical assay for measuring anti-streptokinase antibodies and in this assay the ability of anti-streptokinase antibodies in patients' sera in preventing the lytic ef...

OBJECTIVE To evaluate the influence of pretreatment streptokinase resistance titre and the concentration of IgG antibodies to streptokinase on the efficacy of thrombolytic drugs containing streptokinase in restoring coronary patency in acute myocardial infarction. DESIGN Comparative observational study. SETTING City general hospital. PATIENTS One hundred and twenty four previously unexpos...

Streptokinase activates platelets, limiting its effectiveness as a thrombolytic agent. The role of antistreptokinase antibodies and proteases in streptokinase-induced platelet activation was investigated. Streptokinase induced localization of human IgG to the platelet surface, platelet aggregation, and thromboxane A(2) production. These effects were inhibited by a monoclonal antibody to the pla...

Although there is little doubt that more than one proteolytic enzyme occurs in plasma, plasmin (fibrinolysin) is the only such enzyme which has been definitely identified. Astrup and Permin,12 on the basis of differences in susceptibility to activation by streptokinase and fibrinokinase, have suggested that there are two precursors of fibrinolytic enzymes in human blood. They have designated th...

The purpose of this study was to establish the effects of clot age and thrombolysis, with either streptokinase or tissue-type plasminogen activator (tPA), on argatroban's ability to inhibit thrombin. The antithrombotic activity of argatroban has been quantified in fibrin clot permeation and fibrin clot perfusion systems as a function of clot age and composition. Analysis of the argatroban dose-...